Case 4: A 58-year-old male patient was admitted to the hospital because of fever, nausea and vomiting 30 min after the intake of antituberculous drugs on the first day of therapy. He had pulmonary tuberculosis recognized 8 years ago and antituberculous therapy was initiated for reactivation of pulmonary tuberculosis. He was oliguric and severe acute renal failure developed and required dialysis because of hyperkalemia. After 8 days of oliguria, diuresis was observed and restoration of normal renal function took place in 4 weeks. Case 5: A 42-year-old male patient was on the first month of intermittent tuberculous therapy and developed influenza-like symptoms an hour after the use of the drugs. Laboratory data revealed an acute impairment of renal function without an oliguric phase. Recovery of renal function took place after 5 days and became normal on the 16th day. The laboratory tests for liver function, glucose, lipids, serum electrolytes, LDH, and complement were within the normal limits in all patients. Coagulation was normal and antinuclear antibodies, cryoglobulins, HBs Ag, and Coomb's test were negative. Hemato-logic parameters were normal except for slightly increased WBC count in all patients. High levels of plasma creatinine and BUN were observed (table 1) and uric acid levels were increased in all patients. Urinary examinations showed mild or moderate protein-uria and red and white blood cells with tubular cell casts. Renal ultrasound studies of the patients were normal. Renal tissue was obtained from 2 patients (cases 1 and 4). Histo-pathologic examination showed consistent findings of interstitial nephritis and tubular necrosis without any evidence of vascular or glomerular pathology. We were not able to perform the tests for anti-rifampicin antibodies, but the low dose drug history, flu-like symptoms and clinical findings support the diagnosis of rifampicininduced acute renal failure of immunoaller-gic mechnism [4] . The adverse effects of rifampicin occur especially in patients on intermittent tuberculous therapy or irregular use of the drug as in our patients. Do we have to leave out the intermittent therapy regimen? Of the 4,800 patients who were given intermittent tuberculous therapy, we saw acute renal failure in only 5 (0.1%) since 1978 and all showed recovery of renal function without any complication after discontinuation of the drug and therapy of acute renal failure. As rifampicin is still one of the most effective drugs in tuberculous infections, we conclude that an intermittent therapy regimen should not be given up considering the cost benefits, rarity and reversible nature of rifampicin-in-duced acute renal failure. References
